MedTrace Logo

Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl

NCT02470390 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-03-16

Study results available
· View outcomes & findings →

Summary

A partially randomized, open-label, 3-way crossover, single-center, systemic and CSF PK and bioavailability study in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Fentanyl

Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl

Sponsors & Collaborators

  • Depomed

    lead INDUSTRY

Principal Investigators

  • Head of R&D · Depomed

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-01-31
Completion
2015-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02470390 on ClinicalTrials.gov